Assessing Antibody-Dependent Cell-Mediated Cytotoxicity

Our Director of R&D and Technical Services, Dr. Catriona Thomson recently spoke to ‘Pharmaceutical Technology’ about the challenges of developing and validating an ADCC methodology, including the difference between the classical ADCC assay and the reporter bioassay. To read the full article please click here.

New Video on ADCC Assays from BioOutsource

Rapidly reveals the factors to consider when using ADCC assays for producing precise biosimilar comparability data Glasgow, UK – November 17, 2015: Sartorius Stedim Biotech (SSB) BioOutsource today announced a new video is now available on-line explaining how to overcome the issues associated with using antibody-dependent cell-mediated cytotoxicity (ADCC) assays. The bite-sized video outlines the More

BioOutsource Bioanalysis Experts Attending Major Biosimilar Conferences November 16-19

Offering scientists an opportunity for face-to-face meetings to discuss strategies for accelerating biosimilar development Glasgow, UK – November 12, 2015: Sartorius Stedim Biotech (SSB) BioOutsource today announced its expert technical staff will be speaking at and/or attending BIOLATAM, Biosimilars LATAM and Biosimilars and Biobetters conferences from November 16-19. This will provide developers of biosimilars with More

New Paper on using ADCC Assays to Prove Comparability of Biosimilars

Presents data on factors that affect the sensitivity of ADCC assays and discusses how to optimise methodology Glasgow, UK – November 10, 2015: Sartorius Stedim Biotech (SSB) BioOutsource today announced a new paper entitled, ‘As easy as ADCC’ has been published in the respected journal, European Biopharmaceutical Review. The article outlines the factors affecting the More

As Easy as ADCC

Extensive regulatory requirements for analytical characterisation are now needed to prove comparability between innovator and biosimilar drugs. As a result, many developers are turning to ADCC assays which can help to unpick the issues of similarity, as well as guide the design process to create molecules to target specific activity. Download our article to find out more about the importance More

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.